Allogene Therapeutics Inc (ALLO)

$1.20 -0.01 (-0.83%)
Market Cap 266.26M
Revenue (ttm) 20,000.00
Net Income (ttm) -257.59M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,287,950.01%
Debt to Equity Ratio 0.00
Volume 1,739,900
Avg Vol 3,168,284
Day's Range N/A - N/A
Shares Out 221.88M
Stochastic %K 5%
Beta 0.43
Analysts Strong Sell
Price Target $7.56

Company Profile

Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops, manufactures, and commercializes UCART19, an allogeneic anti-CD19 chimeric antigen receptor (CAR) T cell product candidate for the treatment of patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineer...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 457 2700
Address:
210 East Grand Avenue, South San Francisco, United States
Mr_JokeR
Mr_JokeR Oct. 23 at 2:54 PM
$ALLO Dear Biotech Gods.... you know the rest.
0 · Reply
tradersunion353
tradersunion353 Oct. 21 at 8:38 PM
$ALLO Scam never disappoints insiders who are selling shares Every single day thie scam can close red
1 · Reply
ClenchFists
ClenchFists Oct. 21 at 2:44 PM
$ALLO Loading!!!
0 · Reply
tradersunion353
tradersunion353 Oct. 21 at 2:25 PM
$ALLO Nice . Heading 50 cents Insiders were so confident that this company is heading to rrverse split and eventually chapter 7 Dont bet again insiders ceo cfo who are selling at exponential rate
0 · Reply
Unburdened
Unburdened Oct. 16 at 3:57 PM
$ALLO Why can't this ever hold a gain?? So frustrating
1 · Reply
tradersunion353
tradersunion353 Oct. 16 at 1:35 PM
$ALLO Scam can drop until this scam company files bankruptcy
0 · Reply
DimebagDarrell_
DimebagDarrell_ Oct. 15 at 11:43 PM
$ALLO Nibbled back in today
1 · Reply
tradersunion353
tradersunion353 Oct. 15 at 2:17 PM
$ALLO Garbage will close red
1 · Reply
tradersunion353
tradersunion353 Oct. 14 at 3:52 PM
$ALLO 50 cents and reverse split - guaranteed Scam
1 · Reply
tradersunion353
tradersunion353 Oct. 13 at 2:15 PM
$ALLO $48 to $1 Scam still wants to make nee lows Reverse split coming soon
0 · Reply
Latest News on ALLO
Allogene Therapeutics, Inc. (ALLO) Presents at Citi's SMID Call Series 2025 Transcript

Oct 4, 2025, 12:22 AM EDT - 22 days ago

Allogene Therapeutics, Inc. (ALLO) Presents at Citi's SMID Call Series 2025 Transcript

Allogene Therapeutics Announces Participation in Upcoming Investor Conference

Aug 27, 2025, 8:30 AM EDT - 2 months ago

Allogene Therapeutics Announces Participation in Upcoming Investor Conference

Allogene Therapeutics: Important Catalysts Guided For Early 2026

Aug 14, 2025, 3:02 PM EDT - 2 months ago

Allogene Therapeutics: Important Catalysts Guided For Early 2026

Allogene Therapeutics, Inc. (ALLO) Q2 2025 Earnings Call Transcript

Aug 13, 2025, 9:13 PM EDT - 2 months ago

Allogene Therapeutics, Inc. (ALLO) Q2 2025 Earnings Call Transcript

Allogene Therapeutics Reports Second Quarter 2025 Financial Results and Business Update

Aug 13, 2025, 4:05 PM EDT - 2 months ago

Allogene Therapeutics Reports Second Quarter 2025 Financial Results and Business Update

Allogene Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update

Aug 6, 2025, 8:30 AM EDT - 2 months ago

Allogene Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update

Allogene Therapeutics Moves Forward with Standard Fludarabine and Cyclophosphamide (FC) Lymphodepletion Regimen in the ALPHA3 Trial for Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation for Large B-Cell Lymphoma

Aug 1, 2025, 8:30 AM EDT - 3 months ago

Allogene Therapeutics Moves Forward with Standard Fludarabine and Cyclophosphamide (FC) Lymphodepletion Regimen in the ALPHA3 Trial for Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation for Large B-Cell Lymphoma

Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO

Jun 1, 2025, 10:45 AM EDT - 5 months ago

Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO

Allogene Therapeutics: Buying Around A Potential ASCO Lazarus Moment

May 29, 2025, 3:37 PM EDT - 5 months ago

Allogene Therapeutics: Buying Around A Potential ASCO Lazarus Moment

Allogene Therapeutics: Still Looking Shaky, But Looking To Turn The Corner (Rating Upgrade)

May 28, 2025, 9:43 AM EDT - 5 months ago

Allogene Therapeutics: Still Looking Shaky, But Looking To Turn The Corner (Rating Upgrade)

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

May 23, 2025, 8:30 AM EDT - 5 months ago

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

Allogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-Cel

May 22, 2025, 5:17 PM EDT - 5 months ago

Allogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-Cel

Allogene Therapeutics, Inc. (ALLO) Q1 2025 Earnings Call Transcript

May 13, 2025, 10:47 PM EDT - 5 months ago

Allogene Therapeutics, Inc. (ALLO) Q1 2025 Earnings Call Transcript

Allogene Therapeutics Reports First Quarter 2025 Financial Results and Business Update

May 13, 2025, 4:05 PM EDT - 5 months ago

Allogene Therapeutics Reports First Quarter 2025 Financial Results and Business Update

Allogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update

May 6, 2025, 8:30 AM EDT - 6 months ago

Allogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update

Allogene Therapeutics to Present Updated ALLO-316 Clinical Results in Kidney Cancer in Oral Presentation and ALPHA3 Trial-in-Progress Poster for Cema-Cel at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 23, 2025, 10:12 AM EDT - 6 months ago

Allogene Therapeutics to Present Updated ALLO-316 Clinical Results in Kidney Cancer in Oral Presentation and ALPHA3 Trial-in-Progress Poster for Cema-Cel at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Allogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329, a Next-Generation Dual-Targeted CD19/CD70 Allogeneic CAR T, for the Treatment of Lupus, Myositis and Scleroderma

Apr 7, 2025, 8:30 AM EDT - 7 months ago

Allogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329, a Next-Generation Dual-Targeted CD19/CD70 Allogeneic CAR T, for the Treatment of Lupus, Myositis and Scleroderma

Allogene Therapeutics, Inc. (ALLO) Q4 2024 Earnings Call Transcript

Mar 13, 2025, 11:56 PM EDT - 8 months ago

Allogene Therapeutics, Inc. (ALLO) Q4 2024 Earnings Call Transcript

Allogene Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update

Mar 13, 2025, 4:02 PM EDT - 8 months ago

Allogene Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update

Allogene Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update

Mar 3, 2025, 8:30 AM EST - 8 months ago

Allogene Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update

Allogene: Assessing The Pipeline, Competitive Landscape, And Opportunities

Feb 26, 2025, 10:52 AM EST - 8 months ago

Allogene: Assessing The Pipeline, Competitive Landscape, And Opportunities

Allogene Therapeutics Announces Participation in March Investor Conference

Feb 26, 2025, 8:30 AM EST - 8 months ago

Allogene Therapeutics Announces Participation in March Investor Conference

Allogene Therapeutics Expands Strategic Partnership with Foresight Diagnostics to Advance Joint Development Activities Outside the US Across Europe, UK, Canada, and Australia

Feb 25, 2025, 4:10 PM EST - 8 months ago

Allogene Therapeutics Expands Strategic Partnership with Foresight Diagnostics to Advance Joint Development Activities Outside the US Across Europe, UK, Canada, and Australia

Allogene Therapeutics: Disrupting CAR-T With A Scalable Model

Feb 24, 2025, 10:53 PM EST - 8 months ago

Allogene Therapeutics: Disrupting CAR-T With A Scalable Model

Allogene Therapeutics Announces Publication of Durable Response Data from Phase 1 ALPHA/ALPHA2 Trials of the Allogeneic CAR T Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma in the Journal of Clinical Oncology

Feb 13, 2025, 4:30 PM EST - 9 months ago

Allogene Therapeutics Announces Publication of Durable Response Data from Phase 1 ALPHA/ALPHA2 Trials of the Allogeneic CAR T Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma in the Journal of Clinical Oncology

Allogene Therapeutics Secures U.S. FDA IND Clearance for ALLO-329, Advancing its Next-Generation Allogeneic CAR T into Autoimmune Diseases

Jan 28, 2025, 8:30 AM EST - 9 months ago

Allogene Therapeutics Secures U.S. FDA IND Clearance for ALLO-329, Advancing its Next-Generation Allogeneic CAR T into Autoimmune Diseases

Allogene Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 16, 2024, 8:30 AM EST - 11 months ago

Allogene Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Allogene Therapeutics Acknowledges the Passing of Founding Board Member David Bonderman

Dec 12, 2024, 8:30 AM EST - 11 months ago

Allogene Therapeutics Acknowledges the Passing of Founding Board Member David Bonderman

Allogene Therapeutics Announces Participation in December Investor Conferences

Nov 19, 2024, 8:30 AM EST - 1 year ago

Allogene Therapeutics Announces Participation in December Investor Conferences

Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) Convergence

Nov 18, 2024, 8:30 AM EST - 1 year ago

Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) Convergence

Allogene Therapeutics, Inc. (ALLO) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 8:59 PM EST - 1 year ago

Allogene Therapeutics, Inc. (ALLO) Q3 2024 Earnings Call Transcript

Allogene Therapeutics Reports Third Quarter 2024 Financial Results and Business Update

Nov 7, 2024, 4:02 PM EST - 1 year ago

Allogene Therapeutics Reports Third Quarter 2024 Financial Results and Business Update

Allogene Therapeutics Announces Positive Phase 1 Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Patients with Advanced Renal Cell Carcinoma at SITC and IKCS

Nov 7, 2024, 10:00 AM EST - 1 year ago

Allogene Therapeutics Announces Positive Phase 1 Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Patients with Advanced Renal Cell Carcinoma at SITC and IKCS

Allogene Therapeutics to Present New Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Adult Patients with CD70 Positive Advanced Renal Cell Carcinoma (RCC) at the International Kidney Cancer Symposium (IKCS) and Society for Immunotherapy of Cancer (SITC) Annual Meeting

Nov 5, 2024, 9:10 AM EST - 1 year ago

Allogene Therapeutics to Present New Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Adult Patients with CD70 Positive Advanced Renal Cell Carcinoma (RCC) at the International Kidney Cancer Symposium (IKCS) and Society for Immunotherapy of Cancer (SITC) Annual Meeting

Allogene Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update

Oct 30, 2024, 8:30 AM EDT - 1 year ago

Allogene Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update

Allogene Therapeutics (ALLO) Stock Drops Over 5% Amid Market Activity

Oct 2, 2024, 4:11 PM EDT - 1 year ago

Allogene Therapeutics (ALLO) Stock Drops Over 5% Amid Market Activity

Allogene Therapeutics Announces Participation in the Goldman Sachs Cell Therapy Day Conference

Sep 30, 2024, 8:30 AM EDT - 1 year ago

Allogene Therapeutics Announces Participation in the Goldman Sachs Cell Therapy Day Conference

Allogene Therapeutics: Cema-Cel Promising Among Innovative CAR T-Cell Therapies

Aug 26, 2024, 11:39 PM EDT - 1 year ago

Allogene Therapeutics: Cema-Cel Promising Among Innovative CAR T-Cell Therapies

Allogene Therapeutics, Inc. (ALLO) Q2 2024 Earnings Call Transcript

Aug 10, 2024, 12:34 AM EDT - 1 year ago

Allogene Therapeutics, Inc. (ALLO) Q2 2024 Earnings Call Transcript

Allogene Therapeutics Reports Second Quarter 2024 Financial Results and Business Update

Aug 7, 2024, 4:02 PM EDT - 1 year ago

Allogene Therapeutics Reports Second Quarter 2024 Financial Results and Business Update

Allogene Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update

Jul 31, 2024, 8:30 AM EDT - 1 year ago

Allogene Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update

Allogene Therapeutics Activates Three Community Cancer Centers as First Sites for the Pivotal Phase 2 ALPHA3 Trial Evaluating Cemacabtagene Ansegedleucel (cema-cel) as First Line (1L) Consolidation Treatment for Patients with Large B-Cell Lymphoma (LBCL)

Jul 1, 2024, 8:30 AM EDT - 1 year ago

Allogene Therapeutics Activates Three Community Cancer Centers as First Sites for the Pivotal Phase 2 ALPHA3 Trial Evaluating Cemacabtagene Ansegedleucel (cema-cel) as First Line (1L) Consolidation Treatment for Patients with Large B-Cell Lymphoma (LBCL)

Allogene Therapeutics Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel (cema-cel), an Allogeneic CAR T Product, as Part of First Line Treatment for Patients with Large B-Cell Lymphoma (LBCL) Likely to Relapse

Jun 20, 2024, 8:30 AM EDT - 1 year ago

Allogene Therapeutics Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel (cema-cel), an Allogeneic CAR T Product, as Part of First Line Treatment for Patients with Large B-Cell Lymphoma (LBCL) Likely to Relapse

Allogene: Two End Of 2024 Data Readouts With Improved Allogeneic CAR-T Products

Jun 12, 2024, 1:09 PM EDT - 1 year ago

Allogene: Two End Of 2024 Data Readouts With Improved Allogeneic CAR-T Products

Allogene Therapeutics Announces Participation in the TD Cowen 5th Annual Oncology Innovation Summit

May 23, 2024, 8:30 AM EDT - 1 year ago

Allogene Therapeutics Announces Participation in the TD Cowen 5th Annual Oncology Innovation Summit

Allogene Therapeutics, Inc. (ALLO) Q1 2024 Earnings Call Transcript

May 13, 2024, 7:31 PM EDT - 1 year ago

Allogene Therapeutics, Inc. (ALLO) Q1 2024 Earnings Call Transcript

Allogene Therapeutics Announces Pricing of $110 million Offering of Common Stock

May 13, 2024, 4:47 PM EDT - 1 year ago

Allogene Therapeutics Announces Pricing of $110 million Offering of Common Stock

Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business Update

May 13, 2024, 4:01 PM EDT - 1 year ago

Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business Update

Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update

May 6, 2024, 8:30 AM EDT - 1 year ago

Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update

Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma

Apr 26, 2024, 8:30 AM EDT - 1 year ago

Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma

Mr_JokeR
Mr_JokeR Oct. 23 at 2:54 PM
$ALLO Dear Biotech Gods.... you know the rest.
0 · Reply
tradersunion353
tradersunion353 Oct. 21 at 8:38 PM
$ALLO Scam never disappoints insiders who are selling shares Every single day thie scam can close red
1 · Reply
ClenchFists
ClenchFists Oct. 21 at 2:44 PM
$ALLO Loading!!!
0 · Reply
tradersunion353
tradersunion353 Oct. 21 at 2:25 PM
$ALLO Nice . Heading 50 cents Insiders were so confident that this company is heading to rrverse split and eventually chapter 7 Dont bet again insiders ceo cfo who are selling at exponential rate
0 · Reply
Unburdened
Unburdened Oct. 16 at 3:57 PM
$ALLO Why can't this ever hold a gain?? So frustrating
1 · Reply
tradersunion353
tradersunion353 Oct. 16 at 1:35 PM
$ALLO Scam can drop until this scam company files bankruptcy
0 · Reply
DimebagDarrell_
DimebagDarrell_ Oct. 15 at 11:43 PM
$ALLO Nibbled back in today
1 · Reply
tradersunion353
tradersunion353 Oct. 15 at 2:17 PM
$ALLO Garbage will close red
1 · Reply
tradersunion353
tradersunion353 Oct. 14 at 3:52 PM
$ALLO 50 cents and reverse split - guaranteed Scam
1 · Reply
tradersunion353
tradersunion353 Oct. 13 at 2:15 PM
$ALLO $48 to $1 Scam still wants to make nee lows Reverse split coming soon
0 · Reply
tradersunion353
tradersunion353 Oct. 12 at 9:08 PM
$ALLO This scam will continue to drop One of a classic scam where insiders will keep selling and let company die. Dont fall for paid pumpers
0 · Reply
tradersunion353
tradersunion353 Oct. 11 at 4:24 PM
$ALLO Insiders knew this coming and started selling shares . 50 cents by next weeek Reverse split coming soon
1 · Reply
tradersunion353
tradersunion353 Oct. 10 at 6:56 PM
$ALLO Where did the clowns disappear??
0 · Reply
tradersunion353
tradersunion353 Oct. 10 at 4:56 PM
$ALLO Nice lesson for pumpere here on the board Scam is heading for 50 cents
0 · Reply
AS1980
AS1980 Oct. 10 at 3:11 PM
$ALLO why that fall today ? Anyone ?
3 · Reply
tradersunion353
tradersunion353 Oct. 10 at 3:01 PM
$ALLO Pumpers on this board deserve this.
0 · Reply
tr1llA
tr1llA Oct. 10 at 2:40 PM
$ALLO just dumped, gettin outta here and moving to $ACET
1 · Reply
BugHunti
BugHunti Oct. 10 at 2:11 PM
$ALLO bankruptcy next? fk this, holding this for nearly 2 year.
0 · Reply
tradersunion353
tradersunion353 Oct. 10 at 1:42 PM
$ALLO Heavy Insider selling at $1 range. Stock price dropping from $48 to $1 Analysts downgrades What else does it make to prove this is a scam???
1 · Reply
tradersunion353
tradersunion353 Oct. 10 at 1:17 PM
$ALLO Scam will drop to sub 1s today Never trust a stock where insiders are selling heavily
0 · Reply
JarvisFlow
JarvisFlow Oct. 10 at 11:38 AM
JP Morgan has adjusted their stance on Allogene Therapeutics ( $ALLO ), setting the rating to Underweight.
0 · Reply
notreload_ai
notreload_ai Oct. 10 at 11:07 AM
JPMorgan cuts $ALLO rating to Underweight after company removes CD52 component from cema-cel treatment following fatal event. Near-term outlook remains "challenging." https://notreload.xyz/jpmorgan-downgrades-allogene-therapeutics-safety-concerns/
1 · Reply